业绩总结 - 2023年总收入为4130万美元，2024年预计下降至3860万美元，年增长率为-7%[69] - 2023年总核心收入为2980万美元，2024年预计增长至3250万美元，年增长率为9%[69] - 2023年毛利为3650万美元，毛利率为89%，2024年毛利下降至3150万美元，毛利率为82%[69] - 2023年净亏损为3790万美元，2024年净亏损扩大至4110万美元[69] - 2023年EBITDA为-4410万美元，2024年EBITDA为-4690万美元[69] 用户数据与市场潜力 - 2024年预计收入为3860万美元，非GAAP调整后的毛利率为84%[10] - MaxCyte的市场潜力包括超过12亿美元的基因编辑工具市场和超过60亿美元的遗传载体市场[61] - 截至2024年12月31日，公司现金及现金等价物为1.9亿美元[10] 临床开发与项目进展 - 2024年共筹集资金152亿美元，涉及1950个活跃临床试验[14] - 目前有29个战略平台许可客户，18个项目正在临床开发中[47] - 18个活跃临床项目的预商业里程碑潜力超过2.2亿美元[47] - 公司在2024年已收到约1000万美元的里程碑付款[48] - SPL项目相关收入在2023年为1150万美元，2024年下降至610万美元，年增长率为-47%[69] - SPL项目相关收入占核心收入的57%[68] 技术与研发 - 非病毒程序占所有程序的66%，在临床阶段为50%[19] - 公司拥有超过200项已授予的专利和100项待审专利[37] - ExPERT平台支持从75,000到2000亿细胞的电穿孔处理[31] - 公司在细胞治疗开发中提供行业领先的转染效率和细胞活力[42] 未来展望 - 截至2025年3月31日，非GAAP调整后的毛利率为83%[68] - 截至2025年3月31日，MaxCyte的仪器总安装基数为787台[68]

MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelinesROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission File Number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 52-2210438 (State o ...

MaxCyte (MXCT) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Eric Abdo - Investor RelationsMaher Masoud - President & CEODouglas Swirsky - CFOChad Wiatrowski - VP - Equity ResearchDan Arias - Managing Director Conference Call Participants Matt Larew - Research Analyst - HealthcareJulie Simmonds - Equity Analyst - HealthcareMark Massaro - Managing Director - Senior Equity Research Analyst Operator Good day, and thank you for standing by. Welcome to the MaxSite First Quarter Earnings Con ...

MaxCyte (MXCT) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the MaxSite First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question, please press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that tod ...

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights Exhibit 99.1 "MaxCyte ...

ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights "MaxCyte has had a good start to 2025, with core revenue growth in the first quarter driven by continued strength ...

ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern ...

A downtrend has been apparent in MaxCyte, Inc. (MXCT) lately with too much selling pressure. The stock has declined 27.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, f ...

MaxCyte, Inc. (MXCT) has been on a downward spiral lately with significant selling pressure. After declining 30.2% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a s ...